Author

Taylor Andalis

University of California, San Francisco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Carlos GuijasiD· 2 shared Dylan M. Herbst· 2 shared Aishwarya C. Ballapuram· 1 shared Benjamin F. CravattiD· 1 shared Benjamin J. HuangiD· 1 shared Boer Xie· 1 shared Camille J. Leung· 1 shared Cassandra L. Henry· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Carlos GuijasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Base exchange inhibitors of SARM1 form mononucleotide adducts and activate SARM1 in vivo

Holly T. Reardon, Carlos Guijas, Jason R. Clapper, Julia A. Callender, Ellen M. Kozina, Francisco J. Sarabia, Clayton Hutton, Dylan M. Herbst, Taylor Andalis, Luka Perehinets, Cassandra L. Henry, Terry P. Lebold, David A. Kummer, Jacqueline L. Blankman, John J. M. Wiener, , Tarek A. Samad

The paper shows that SARM1 base exchange inhibitors form mononucleotide adducts and paradoxically activate SARM1, leading to increased cADPR and cADPR/NAD ratios in vivo.

bioRxiv · Apr 22, 2025 · PreprintNeuroscience

In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer

Matthew Decker, Benjamin J. Huang, Timothy B. Ware, Christopher D. Boone, Michelle Tang, Julia Ybarra, Matthew J. Sale, Rony A. Francois, Aishwarya C. Ballapuram, Katrine A. Taran, Esteban Tarazona-Guzman, Pan-Yu Chen, Marcos Armendariz, Camille J. Leung, Max Harris, , Kevin Shannon

This study validates the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers by showing that inhibiting ABHD17 reduces tumor growth and synergizes with MEK inhibitors.

bioRxiv · Mar 20, 2025 · PreprintCancer Biology